Roche and Trimeris apply for FDA approval of Fuzeon
BY Advocate.com Editors
September 19 2002 12:00 AM ET
Drugmakers Roche and Trimeris on Tuesday applied to the Food and Drug Administration for approval of their new anti-HIV drug Fuzeon, formerly known as T-20, The Wall Street Journal reports. The companies requested a priority six-month review for the compound and hope to have it on the market in the first quarter of 2003. Fuzeon is the drug in a new class of medications called entry or fusion inhibitors, which work outside the body's cells by preventing HIV from attaching to and infecting them. The FDA application requested review for Fuzeon as part of combination therapy to treat HIV infection.
Roche and Trimeris officials say the drug is designed to treat patients whose HIV has become resistant to other antiretroviral drugs. The companies plan to file for European Union approval of the drug by the end of the month. Analysts say that a year's supply of the drug, which must be
injected, will cost between $10,000 and $15,000.
- This Is How Every Parent Should Respond After Their 13-Year-Old Comes Out
- From The Archives: The Groovy Guy, '69
- Throwback Thursday: Richard Simmons Gets Inappropriate on Whose Line Is It Anyway?
- Op-ed: In Defense of Looking
- Derek Jarman's Alternative to The New Gay Credo
- After Elimination: Vivacious of RuPaul's Drag Race Season 6
- Current Issue Experts Predict: Iran Will Remain Deadly 34 min 16 sec ago
- Transgender How New Immigration Detention Guidelines Fail Trans Inmates 42 min 11 sec ago
- Travel Destination of the Week: Denmark March 13 2014 7:41 PM
- Women WATCH: Daughter Teaches Mom Lesbian Slang March 13 2014 7:27 PM
- Women What do the OINTB Season 2 Promo Pics Mean for the Ladies of Litchfield? March 13 2014 7:14 PM
- Women BREAKING: Father of Murdered Texas Lesbian Arrested March 13 2014 6:34 PM
- Travel Directors, Reality Housewives and the Sad Story of WeHo's 'Death Corner' March 13 2014 5:33 PM